
Bioretec Q2'25: Slower sales development than expected
Bioretec's weak Q2 earnings were a disappointment compared to expectations. The company's revenue and gross margin % decreased sharply, and the simultaneous increase in operational costs doubled the operating loss. Bioretec's interim CEO Sarah Hubar-Fisher provides more details in an interview with analyst Antti Siltanen.
Topics
00:00 Introduction
00:13 Q2 summary
02:18 Negative revenue impact of ended Spartan Medical distribution deal
03:06 Weak performance in Europe and the United States
05:46 Status of country-specific processes in terms of RemeOs sales
06:55 Expectations for the rest of…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.